loading page

Integration of ceritinib and bevacizumab as a promising treatment strategy for brain metastases from ALK mutation-position non-small cell lung cancer: a case report
  • +5
  • Yinxue Xia,
  • Shuhe Lu,
  • Weixi Shen,
  • Tao Xin,
  • Chengjuan Fan,
  • Chong Teng,
  • Xiaowei Song,
  • Yanju Lv
Yinxue Xia
Harbin Medical University
Author Profile
Shuhe Lu
Harbin Medical University
Author Profile
Weixi Shen
Second Affiliated Hospital of Harbin Medical University
Author Profile
Tao Xin
Second Affiliated Hospital of Harbin Medical University
Author Profile
Chengjuan Fan
Second Affiliated Hospital of Harbin Medical University
Author Profile
Chong Teng
Second Affiliated Hospital of Harbin Medical University
Author Profile
Xiaowei Song
Second Affiliated Hospital of Harbin Medical University
Author Profile
Yanju Lv
Second Affiliated Hospital of Harbin Medical University
Author Profile

Abstract

Ceritinib shows efficacy in ALK+ NSCLC patients with BM. However, the disease will inevitably progress over time due to acquired resistance. We now report a case with BM from advanced lung adenocarcinoma with ALK mutations who exhibited a surprising and long-term response to treatment of ceritinib combined with bevacizumab.

Peer review status:ACCEPTED

20 Mar 2021Submitted to Clinical Case Reports
22 Mar 2021Submission Checks Completed
22 Mar 2021Assigned to Editor
25 Mar 2021Reviewer(s) Assigned
10 Apr 2021Review(s) Completed, Editorial Evaluation Pending
10 Apr 2021Editorial Decision: Revise Minor
09 May 20211st Revision Received
11 May 2021Submission Checks Completed
11 May 2021Assigned to Editor
11 May 2021Review(s) Completed, Editorial Evaluation Pending
14 May 2021Editorial Decision: Accept